

News Release

Xantrex™ appoints Bruce Cousins as Vice President and Chief Financial Officer

VANCOUVER, B.C., April 22, 2008 – Xantrex Technology Inc. (TSX:XTX) has appointed Bruce Cousins as its Chief Financial Officer effective June 1, 2008. Jay Biskupski, former Chief Financial Officer, is no longer with Xantrex. Sarah MacKinnon, currently Director of Finance, has been appointed Interim Chief Financial Officer for the period from April 23 to May 31, 2008.

John Wallace, Xantrex's Chief Executive Officer, commented, "Bruce will assume a leadership role to advance the financial and operational strategy at Xantrex in support of our growth objectives. We believe Bruce has the right skills and experience for this challenging position and we are all looking forward to working with him."

Mr. Cousins has been with Aspreva Pharmaceuticals Corporation since March 2004 as Executive Vice President and Chief Financial Officer. Aspreva was a public company listed on the NASDAQ and TSX that was recently acquired by Galencia AG on January 3, 2008. From 1990 to 2004, Mr. Cousins served in various senior finance and operations positions at Johnson & Johnson, a pharmaceutical company. From 1987 to 1990, Mr. Cousins was with Deloitte & Touche LLP.

About Xantrex

Xantrex Technology Inc. (www.xantrex.com) is a world leader in the development, manufacturing and marketing of advanced power electronic products and systems for the renewable, programmable, and mobile power markets. The company's products convert and control raw electrical power from any central, distributed, renewable, or backup power source into high-quality power required by electronic and electrical equipment. Headquartered in Vancouver, British Columbia, the company has facilities in Arlington, Washington; Livermore and San Diego, California; Elkhart, Indiana; Barcelona, Spain; and Reading, England. Xantrex is listed on the Toronto Stock Exchange under the ticker symbol "XTX".

Note that this news release contains forward-looking statements related to Xantrex Technology Inc. Such statements reflect the current views of Xantrex with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in these forward-looking statements. Xantrex and Smart choice for power are trademarks of Xantrex International, registered in the United States and other countries.

For further information, please contact:
Investor Relations
(604) 422-2601
investor.relations@xantrex.com